OncMadness: Meet the Blue Ribbon Panel – MedPage Today

OncMadness 2020 is upon us.

In this first-of-its-kind online education competition in oncology by oncologists, hosted by MedPage Today, 32 oncology hot topics will face off -- only one can be champion! Helping MedPage Today are nine key oncology opinion leaders who will vote on their top choices and create the winning bracket.

Let's meet our Blue Ribbon Panel:

Lisa A. Carey, MD

Carey is the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research, and board-certified in medical oncology. She is the Chief of Hematology/Oncology, the Physician-in-Chief of N.C. Cancer Hospital, and Associate Director of Clinical Sciences at Lineberger Comprehensive Cancer Center. Carey's research and clinical interests focus on breast cancer, including examination of different subtypes of breast cancer, evaluation of new chemotherapy agents in early breast cancer, and examination of tumor characteristics that predict response to therapy.

Don Dizon, MD

Dizon is Director of Women's Cancers at Lifespan Cancer Institute, Clinical Director of Gynecologic Medical Oncology and Director of Medical Oncology at Rhode Island Hospital, and a professor of medicine at the Warren Alpert Medical School of Brown University. His research interests are in novel treatments of women's cancers and issues related to survivorship, particularly as they relate to sexual health after cancer for both men and women. Twitter: DrDonSDizonM

Edward S. Kim, MD

Kim is a national leader in the field of oncology, recognized for his work in molecular prognostication for lung cancer. He is Chair of the Department of Solid Tumor Oncology & Investigational Therapeutics at Atrium Health's Levine Cancer Institute in North Carolina. Kim studies novel targeted agents in the treatment and prevention settings and has expertise in lung and head and neck cancers. He chaired the Department of Defense Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program in lung cancer. Twitter: EdKimMDLCI

Nancy Y. Lee, MD

Lee is Vice Chair, Department of Radiation Oncology; Service Chief, Head & Neck Radiation Oncology; and Director, Proton Therapy, all at Memorial Sloan Kettering Cancer Center. Lee specializes in using advanced forms of radiation to treat head and neck cancer, including thyroid cancer. These include proton therapy, intensity-modulated radiation therapy (IMRT), image-guided radiation therapy, and stereotactic body radiation therapy. She serves as principal investigator for the Radiation Therapy Oncology Group (RTOG) in a national trial to refine use of IMRT for treating nasopharyngeal cancer. Lee was a co-author on the Cancer Immunotherapy Guidelines for Head and Neck Cancer put forward by the Society for Immunotherapy of Cancer. She sits on the editorial board of the Journal of Radiation Oncology.

Sagar Lonial, MD

Internationally recognized as a leading authority in multiple myeloma treatment and research, Lonial is Professor and Chair of the Department of Hematology & Medical Oncology at Emory University, a medical oncologist at the Winship Cancer Institute, and a lead member of the bone marrow transplantation team and clinical trials team. He collaborates with leadership as Chief Medical Officer to coordinate and enhance clinical services and patient care throughout Winship. Twitter: SagarLonialMD

John L. Marshall, MD

Marshall is Chief of the Division of Hematology/Oncology at Medstar Georgetown University Hospital, Professor of Medicine and Oncology at Lombardi Comprehensive Cancer Center at Georgetown University, and Director of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer. Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design. His primary focus has been on the development of vaccines to treat cancer.

David Penson, MD, MPH

Penson is the Paul V. Hamilton, MD, and Virginia E. Howd Chair in Urologic Oncology and Professor of Urologic Surgery and Medicine at Vanderbilt University Medical Center, and Director of the Vanderbilt Center for Surgical Quality and Outcomes Research in the Vanderbilt Institute for Medicine and Public Health. Penson's primary research interest is in population-based cohorts and assessing patient-reported outcomes in conditions treated with surgical procedures, specifically prostate cancer.

John Sweetenham, MD

Sweetenham is Professor of Internal Medicine at UT Southwestern Medical Center and Associate Director for Clinical Affairs at UTSW's Harold C. Simmons Comprehensive Cancer Center. An internationally recognized expert in the treatment of hematologic malignancies, his central research interest is lymphoma and the use of stem cell transplantation. Prior to joining the UT Southwestern faculty in 2019, Sweetenham was Senior Director for Clinical Affairs and Physician-in-Chief at the Huntsman Cancer Institute of the University of Utah.

Alan Venook, MD

Venook is Shorenstein Associate Director for Program Development in the Helen Diller Family Comprehensive Cancer Center and Professor of Medicine (Hematology/Oncology) and UCSF Madden Family Distinguished Professor in Medical Oncology and Translational Research at the University of California San Francisco. Venook has experience and expertise in clinical trial design in gastrointestinal malignancies and is current Chair of the Gastrointestinal Committee of the Alliance for Clinical Trials in Oncology.

Originally posted here:
OncMadness: Meet the Blue Ribbon Panel - MedPage Today

Related Post